Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 12, 2026, 10:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–17 of 17 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: KIT Positive Clear all
Completed Not applicable Interventional Results available

Study Evaluating the Timing of Intrauterine Insemination in Relation to Positive Home Ovulation Prediction Kit

NCT02294773
View directory record Official record
Conditions
Infertility
Interventions
Intrauterine Insemination, Clomiphene, Letrozole
Procedure · Drug
Lead sponsor
Midwest Fertility Specialists
Industry
Eligibility
21 Years to 39 Years · Female only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
2
States / cities
Fort Wayne, Indiana • Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Dec 8, 2015 · Synced Sep 12, 2026, 10:32 AM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Safety and Pharmacokinetics of CDX-0158 in Adult Patients With Advanced Solid Tumors

NCT02642016
View directory record Official record
Conditions
Advanced Cancer
Interventions
CDX-0158 (formerly known as KTN-0158)
Biological
Lead sponsor
Celldex Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
4
States / cities
Boston, Massachusetts • Portland, Oregon • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 11, 2019 · Synced Sep 12, 2026, 10:32 AM EDT
Completed Phase 4 Interventional Results available

Study to Allow Access to Nilotinib for Patients Who Are on Nilotinib Treatment in a Novartis-sponsored Study

NCT01735955
View directory record Official record
Conditions
Chronic Myelogenous Leukemia (CML), Metastatic Gastrointestinal Stromal Tumors (GIST), Acute Lymphoblastic Leukemia (ALL), Receptor Tyrosine Kinase (KIT) Mutated Melanoma
Interventions
Nilotinib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
Not listed
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2023
U.S. locations
2
States / cities
Albany, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 7, 2024 · Synced Sep 12, 2026, 10:32 AM EDT
Not listed Not applicable Interventional

Genotypic Versus Phenotypic Susceptibility Testing of Positive Blood Cultures

NCT03744728
View directory record Official record
Conditions
Bloodstream Infection
Interventions
Accelerate PhenoTest™ BC kit, Standard of Care
Diagnostic Test
Lead sponsor
Accelerate Diagnostics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
774 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 21, 2022 · Synced Sep 12, 2026, 10:32 AM EDT
Completed No phase listed Observational

Febrile Whole Blood Specimen Collection and Testing

NCT03498027
View directory record Official record
Conditions
Febrile Infection, Anthrax
Interventions
TaqMan Bacillus anthracis Detection Kit
Device
Lead sponsor
MRI Global
Industry
Eligibility
2 Years to 89 Years
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
3
States / cities
Tarpon Springs, Florida • Fall River, Massachusetts • Franklin, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 18, 2018 · Synced Sep 12, 2026, 10:32 AM EDT
Completed Phase 2 Interventional Results available

Dasatinib as Therapy for Myeloproliferative Disorders (MPDs)

NCT00255346
View directory record Official record
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndromes, Agnogenic Myeloid Metaplasia, Myelofibrosis, Hypereosinophilic Syndrome, Polycythemia Vera, Mastocytosis, Leukemia, Myelomonocytic, Chronic
Interventions
Dasatinib (BMS-354825)
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 29, 2025 · Synced Sep 12, 2026, 10:32 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

This Study Evaluates the ALPCO Syphilis-T and Syphilis-NT CLIA Kits for Detecting Syphilis Antibodies in Serum and Plasma. Samples From At-risk, HIV-positive, Pregnant, and Healthy Individuals Will Assess Assay Performance Versus Established Comparator Tests.

NCT07089836
View directory record Official record
Conditions
Treponema Pallidum, Treponema Pallidum Infection, Syphilis Infection, Serum, Plasma, Blooddraw, Sexually Transmitted Infection (STI)
Interventions
ALPCO Syphilis-T, ALPCO Syphilis-NT CLIA Kits
Device
Lead sponsor
American Laboratory Products Company
Industry
Eligibility
13 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
6
States / cities
Lancaster, California • Los Angeles, California • North Miami, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Sep 12, 2026, 10:32 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Clinical Performance and Reproducibility of the Accelerate PhenoTest™ Blood Culture (BC) Kit With New Antibiotic Wave I Updates

NCT04295915
View directory record Official record
Conditions
Bacteremia
Interventions
Specimens that meet inclusion criteria
Device
Lead sponsor
Accelerate Diagnostics, Inc.
Industry
Eligibility
Not listed
Enrollment
731 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
3
States / cities
Tucson, Arizona • Hershey, Pennsylvania • Lewisville, Texas
Source: ClinicalTrials.gov public record
Updated Apr 21, 2022 · Synced Sep 12, 2026, 10:32 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Clinical Concordance Evaluation of T-SPOT®.TB Assay Performance (T-Cell SelectTM Study)

NCT04141982
View directory record Official record
Conditions
Tuberculosis
Interventions
T-Cell SelectTM Kit
Diagnostic Test
Lead sponsor
Oxford Immunotec
Industry
Eligibility
18 Years and older
Enrollment
680 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
3
States / cities
Fall River, Massachusetts • Columbus, Ohio • Brownsville, Texas
Source: ClinicalTrials.gov public record
Updated Mar 2, 2022 · Synced Sep 12, 2026, 10:32 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

300 Antibody Diagnostic Test Kit

NCT01646411
View directory record Official record
Conditions
Acute Bacterial Infections, Acute Viral Infections
Interventions
Not listed
Lead sponsor
The Plasma Source
Industry
Eligibility
18 Years to 70 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Southampton, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 19, 2012 · Synced Sep 12, 2026, 10:32 AM EDT
Completed Phase 2 Interventional

Gleevec/Low-Dose Ara-C Study for Elderly Patients With AML and Myelodysplastic Syndromes

NCT00451997
View directory record Official record
Conditions
Leukemia, Myeloid, Myelodysplastic Syndromes
Interventions
Gleevec, Ara-C
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
60 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 31, 2012 · Synced Sep 12, 2026, 10:32 AM EDT
Completed Phase 2 Interventional Results available

Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Vulvovaginal Melanoma That Cannot Be Removed By Surgery

NCT00700882
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
dasatinib
Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2020
U.S. locations
153
States / cities
Little Rock, Arkansas • Stanford, California • Fort Lauderdale, Florida + 106 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2023 · Synced Sep 12, 2026, 10:32 AM EDT
Completed Phase 2 Interventional Results available

Letrozole and Imatinib Mesylate in Treating Postmenopausal Participants With Estrogen or Progesterone Positive Metastatic Breast Cancer

NCT00338728
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor Positive, KIT Positive, PDGFR Positive, Postmenopausal, Progesterone Receptor Positive, Prognostic Stage IV Breast Cancer AJCC v8
Interventions
Imatinib Mesylate, Letrozole
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Female only
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 26, 2020 · Synced Sep 12, 2026, 10:32 AM EDT
Completed Phase 2 Interventional

Preoperative and Postoperative Imatinib Mesylate Study in Patients With c-Kit Positive GIST

NCT00500188
View directory record Official record
Conditions
Gastrointestinal Stromal Tumors
Interventions
Imatinib Mesylate (Gleevec)
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 7, 2011 · Synced Sep 12, 2026, 10:32 AM EDT
Completed Phase 2 Interventional

Gleevec Maintenance Therapy After Induction Irinotecan and Cisplatin in Patients With C-Kit Positive Extensive SCLC

NCT00156286
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
Gleevec
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 15, 2010 · Synced Sep 12, 2026, 10:32 AM EDT
Completed Phase 1 Interventional

Imatinib Mesylate, Daunorubicin, and Cytarabine in Treating Patients With Relapsed Acute Myeloid Leukemia

NCT00268229
View directory record Official record
Conditions
Leukemia
Interventions
cytarabine, daunorubicin hydrochloride, imatinib mesylate
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 14, 2013 · Synced Sep 12, 2026, 10:32 AM EDT
Completed Phase 2 Interventional Results available

Imatinib Mesylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Who Have Received Chemotherapy

NCT00509093
View directory record Official record
Conditions
Leukemia
Interventions
imatinib mesylate, gene expression analysis, mutation analysis, polymerase chain reaction, flow cytometry, biopsy
Drug · Genetic · Other + 1 more
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
4
States / cities
Buffalo, New York • Durham, North Carolina • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 16, 2020 · Synced Sep 12, 2026, 10:32 AM EDT